Literature DB >> 14528912

CU(II)-catalyzed oxidation of Alzheimer's disease beta-amyloid peptide and related sequences: remarkably different selectivities of neurotoxic betaAP1-40 and non-toxic betaAP40-1.

C Schöneich1, T D Williams.   

Abstract

We investigated the CuII-catalyzed oxidation of beta-amyloid peptides betaAP10-20 and betaAP40-1 by tandem mass spectrometry and compared oxidation yields and selectivities to those for betaAP1-16, betaAP1-28 and betaAP1-40, which were obtained earlier (26). While betaAP1-16, betaAP1-28 and betaAP1-40 showed an almost exclusive oxidation of His residues to 2-oxo-histidine, the selectivity pattern is changed for betaAP10-20,which shows oxidation of His but also hydroxylation of Tyr and Phe. In contrast to betaAP1-40, the reverse sequence betaAP40-1 shows a strong selectivity for the hydroxylation of Tyr31 while only negligible His oxidation is observed at early time points. These selectivity patterns show the importance of the geometry of the metal-binding site for peptide/protein oxidation. The significantly different characteristic of betaAP1-40 and betaAP40-1 with regard to metal catalyzed processes may be related to the differences in the neurotoxic properties of these sequences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528912

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  3 in total

1.  Identification of specific protein carbonylation sites in model oxidations of human serum albumin.

Authors:  Ani Temple; Ten-Yang Yen; Scott Gronert
Journal:  J Am Soc Mass Spectrom       Date:  2006-06-05       Impact factor: 3.109

2.  Identification of 2-oxohistidine Interacting Proteins Using E. coli Proteome Chips.

Authors:  Jun-Mu Lin; Yu-Ting Tsai; Yu-Hsuan Liu; Yun Lin; Hwan-Ching Tai; Chien-Sheng Chen
Journal:  Mol Cell Proteomics       Date:  2016-09-19       Impact factor: 5.911

3.  Fluorogenic tagging methodology applied to characterize oxidized tyrosine and phenylalanine in an immunoglobulin monoclonal antibody.

Authors:  Shuxia Zhou; Olivier Mozziconacci; Bruce A Kerwin; Christian Schöneich
Journal:  Pharm Res       Date:  2013-02-15       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.